Valeant Pharmaceuticals International (VRX) · page 20 of 47
The table uses a low/mid/high scenario approach to calculate value creation based on multiples of 2014 Pro-Forma Free Cash Flow.
Conference presentation · valuation_table · quantify_opportunity · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
callout 1/1 disclaimer 1/1 list 1/1 paragraph 1/1 table 1/1 title 1/1
Components 6
primary disclaimer bullet paragraph valuation headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1